Page d'accueil  |  Aide  |  Effacer
Anglais  |  Français
 Rechercher  |  Catégories  |  Titres A-Z  |  Pays  |  Comparer pays  |  Index  
Etendre sommaire
Document complet
Dérouler chapitre
Préférences

fermer ce livreGuidelines to Antiretroviral Drug Therapy in Kenya (WHO; 2001; 78 pages)
Afficher le documentFOREWORD
Afficher le documentACKNOWLEDGMENT
ouvrir ce répertoire et afficher son contenuCHAPTER ONE: INITIATING ANTIRETROVIRAL THERAPY
ouvrir ce répertoire et afficher son contenuCHAPTER TWO: MONITORING AND CHANGING THERAPY
ouvrir ce répertoire et afficher son contenuCHAPTER THREE: PHARMACOTHERAPEUTICS OF ARVS
ouvrir ce répertoire et afficher son contenuCHAPTER FOUR: GUIDELINES FOR THE USE OF ANTIRETROVIRAL DRUGS IN PAEDIATRIC HIV INFECTION
ouvrir ce répertoire et afficher son contenuCHAPTER FIVE: MANAGEMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED PREGNANT WOMEN AND PREVENTION OF MOTHER TO CHILD TRANSMISSION (MTCT) OF HIV
ouvrir ce répertoire et afficher son contenuCHAPTER SIX: SPECIAL CONSIDERATIONS
ouvrir ce répertoire et afficher son contenuCHAPTER SEVEN: WHEN TO STOP TREATMENT (INTERRUPTIONS)
ouvrir ce répertoire et afficher son contenuCHAPTER EIGHT: GUIDELINES FOR POST EXPOSURE PROPHYLAXIS
Afficher le documentCHAPTER NINE: ACCESS TO DRUGS IN KENYA
fermer ce répertoireAPPENDICES
Afficher le documentI. Drug to drug interactions
Afficher le documentII. Drug to drug interactions (continued)
Afficher le documentIII. Drug Interactions Between Antiretrovirals and Other Drugs
Afficher le documentIV. Nucleoside Reverse Transcriptase Inhibitors (NRTIS)
Afficher le documentV. Drug Interactions: Protease Inhibitors
Afficher le documentVI. Drug Interactions: Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors - Cont.
Afficher le documentVII. Drug That Should Not be Used With Antiretrovirals
Afficher le documentVIII. Drugs that should not be used with Protease Inhibitors Antiretrovirals
Afficher le documentIX. HIV-related drugs with overlapping toxicities
Afficher le documentX. Anti-retroviral therapy for preventing MTCT
Afficher le documentBACK COVER
 

X. Anti-retroviral therapy for preventing MTCT

STUDY

DRUG

ANTEPARTUM

INTRAPARTUM

POSTPARTUM

INFANT

REDUCTION IN MTCT

PACTOG 076
Non Breast feeding

AZT

100 mg p.o. 5 times daily starting at 14-34 week gestation.

1v 2mg/kg loading, then 1 mg/kg/hr

No

2mg/kg p.o. 6 hourly for 6 weeks

68% (infection status at 18 months

Thailand
Non breast feeding

AZT

300 mg p.o. bd, p.o starting at 36 weeks gestation

300mg p.o 3hrly

No

No

50% (infection status at 6 months age)

Cote D voire
Breast feeding

AZT

300 mg p.o. Bd, p.o. starting at 36 weeks gestation

300mg p.o 3hrly

No

No

47% (infection status at 6 weeks age)

Cote D voire
Burkina Faso
breast feeding

AZT

300 mg p.o. bd, starting at 36 weeks gestation

600mg p.o at the onset of labour

300mg bd for 1 week

No

38% (infection status at 6 months age)

Africa-Petra
Arm A 67%
Breast feeding

AZT +3TC

300mg AZT + 150mg +3TC . starting at 36 weeks gestation

300mg AZT+ 150mg 3TC p.o 3 hourly

300mg AZT + 150mg 3TC p.o bd for 1 week

AZT 4mg/kg + 3TC 2mg/ kg p.o bd for 1 week

38% (infection status at 6 months age)

Africa-Petra
Arm B 67%
Breast feeding

AZT 300mg +3TC 150mg (combivir)

No

300mg AZT+ 150mg 3TC p.o 3 hourly

300mg AZT + 150mg 3TC p.o bd for 1 week

AZT 4mg/kg + 3TC 2mg/ kg p.o bd for 1 week

37% (infection status at 6 weeks age)

VIVNET
Breast feeding

 

No

200mg single dose at the onset of labor

No

2mg/kg single dose in the first 72 hours

47% (infection status at 6 weeks)

Design, layout, colour separations and printing done by
TESSA Productions Co. Ltd. Box 418 Sarit centre: Tel: 443248/446570

vers la section précédentevers la section suivante

S'il vous plaît envoyez vos commentaires Anglais  |  Français